Comprehensive analysis of obeticholic acid tablets: drug properties, indications and medication guidance

Obeticholic acid, chemical nameObeticholic acid, is a synthetic bile acid analogue with powerful farnesolide X nuclear receptor (FXR) agonistic activity. FXR plays a crucial role in the production and transport of bile acids and the metabolic balance of lipids and glucose in the human body. Due to its unique role in regulating these physiological processes, obeticholic acid has been shown to be effective in improving serum enzyme levels in a variety of liver diseases, including primary biliary cholangitis (PBC).

Primary biliary cholangitis, a chronic liver disease that seriously affects the health of the biliary system. If left untreated, inflammation and fibrosis caused by cholestasis may lead to a gradual decline in liver function. Obeticholic acid is an important treatment drug for this disease. It is suitable for patients with no evidence of cirrhosis or only compensated cirrhosis without evidence of portal hypertension. During treatment, obeticholic acid can be used in combination with ursodeoxycholic acid (UDCA) or as monotherapy in patients with UDCA intolerance. Approval for this indication was based on clinical trial data on alkaline phosphatase (ALP) reduction.

Obeeticholic acid is available in two tablet sizes: 5 mg and 10 mg, with the trade name Ocaliva. For patients with primary cholangitis, the recommended initial dose is 5 mg per day, which can be gradually increased to 10 mg per day depending on the condition. During medication, patients may experience side effects such as itching, fatigue, nausea, and headache. Itching may be relieved if you start with a low dose and gradually increase the dose. Therefore, when using obeticholic acid for treatment, doctors will develop a personalized medication plan based on the patient's specific situation and closely monitor possible side effects to ensure the safety and effectiveness of the treatment.